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Background:  The  potential  for  development  of  autoimmune  diseases  after  vaccination  with  new  vaccines
containing  novel  adjuvants  is  a theoretical  concern.  Randomised,  placebo-controlled  trials  are  the  best
method for  assessing  a potential  causal  relationship  between  an  adverse  event  and  vaccination,  but
usually  have  a sample  size  too  small  to detect  adverse  events  occurring  in <1%  of  subjects.  Incomplete
case  documentation  may  hamper  deﬁnitive  diagnoses,  preventing  accurate  causality  assessment.  To date
there  are  no  guidelines  for collection,  documentation  and  monitoring  of  potential  immune  mediated
disorders  (pIMD)  reported  in the  course  of  clinical  trials  with  adjuvanted  vaccines.
Objective:  This  paper  proposes  a  methodology  for  collection  of  pIMDs  in  clinical  vaccine  trials,  with  the
objective  of  obtaining  complete  and reliable  data  using  standardised  methodology  for its  collection  and
analysis.
Recommendations:  The  role  of  the  study  investigator  in  prospective,  standardised  safety  data  collection
is  key  and  can be facilitated  by providing  a pIMD  list  in study  documents  and  disease-speciﬁc  standard
questionnaires  to  assist  timely  and  thorough  documentation.  External  expert  review  of  histopathology
samples  or  other  specialised  diagnostic  data  would  increase  diagnostic  accuracy.  Centralised  case  ascer-
tainment  using  standard  case  deﬁnitions  would  identify  true cases  of  interest.  We  propose  collection  of
safety data  for  at least  6  months  and  up  to  one  year  after  the  last  vaccine  dose.  Bio-banking  as  a platform
for  collecting  samples  from  enrolled  patients  for future  use  (e.g.,  to measure  biomarkers  of  diagnostic,
prognostic  or predictive  utility)  could  eventually  provide  valuable  information  in cases  where  a pIMD  is
diagnosed  during  the  study  period.
Conclusion:  Standardised  collection  of  safety  data  to allow  appropriate  analyses  are  optimal  approaches
for  detecting  rare events  in  clinical  trials.  Appropriate  data  analysis  will  then  more  reliably  deﬁne  poten-
ith  vtial causal  relationships  w
. Introduction
Adjuvants are used in vaccines to direct and enhance immune
esponses to target antigens. For around 80 years the only adjuvant
sed in human vaccines was aluminium salts. However, a grow-
ng number of new generation vaccines employing novel adjuvants
Abbreviations: AESI, adverse events of special interest; pIMD, potential immune
ediated disease.
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have become available in the last 20 years [1].  Regulatory author-
ities, health care professionals and the general public regularly
question the safety of new generation vaccines, particularly their
possible effects on the regulation of the immune system and the
potential (yet theoretical) concern for the development of autoim-
mune syndromes after vaccination.
Autoimmunity results from complex interactions between
genetic traits and environmental factors, and can be triggered by a
number of stimuli. Infections have long been proposed as environ-
mental triggers for the induction of autoimmunity. For example,
Open access under CC BY-NC-ND license.Campylobacter jejuni infection is linked with the occurrence of
Guillain-Barré syndrome, associated with a cross-reacting anti-
ganglioside antibody response [2].  However, most infections and
virtually all vaccinations in humans, except for the administration
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f an old rabies vaccine that was cultivated on rabbit brain tis-
ue [2],  lack well-established links to autoimmune diseases. Case
eports of autoimmune diseases temporarily associated with the
dministration of vaccines (both adjuvanted and non-adjuvanted)
ave been described in the scientiﬁc literature [3].  Most of these
eports refer to vaccines targeting viral illnesses [4,5]. Proposed
echanisms by which vaccines might induce autoimmune diseases
re frequently extrapolated from the known capacity of the infec-
ious agents that the vaccine targets [3,6–10]. For vaccines targeting
iral illnesses, this hypothesis is supported by animal models of
irus-induced autoimmunity [11]. Among reports of autoimmune
iseases for which vaccination has been suspected as the trigger
n predisposed individuals, only a few have been well described
nd documented [2,3,12]. For example, an association between the
nset of Guillain-Barré syndrome and inﬂuenza vaccination was
laimed during the 1976–1977 swine ﬂu immunisation campaign
n the United States (but not in subsequent campaigns) [13–16];
imilarly, idiopathic thrombocytopenic purpura was associated
ith the administration of combined measles-mumps-rubella
accination in children [17]. By contrast, large epidemiological
tudies have failed to show associations between hepatitis B vac-
ination and demyelinating diseases including multiple sclerosis
18–20].
Systematic pre- and post-licensure monitoring of vaccine safety
s critical in providing ongoing evaluation and signal detection
f new or unexpected adverse events occurring after vaccina-
ion. Prospective collection and analysis of adverse events of
pecial interest (AESIs) is essential in well-conducted clinical trials.
ncomplete detail to support a given diagnosis and/or to consider
ther possible causes is one of the frequent limitations in their
valuation.
To date there are no speciﬁc guidelines for collection, docu-
entation and monitoring of potential immune mediated disorders
pIMD) as AESIs reported in the course of clinical trials with adju-
anted vaccines. This paper proposes a standardised methodology
ased on experience gathered in the past few years, for the prospec-
ive collection of pIMDs in vaccine clinical trials sponsored by
laxoSmithKline Vaccines, with the objective of obtaining com-
lete and reliable data and for its analysis.
. Collection of potential immune mediated disorders in
linical trials
The pIMDs are a subset of immune mediated inﬂamma-
ory disorders which may  or may  not have an autoimmune
etiology. In immune mediated inﬂammatory disorders, tissue
amage results from self-directed inﬂammation due to activation
f innate immune cells, including macrophages and neutrophils.
y contrast, autoimmune diseases can be classiﬁed as inﬂam-
ation against self that is mediated by the adaptive immune
ystem, with development of immune reactivity towards native
ntigens. Hyper-reactivity of both T and B cells (as well as
berrant dendritic cells) is typically observed in conjunction
ith autoantibodies and antigen-speciﬁc T cells targeting self,
esulting in tissue destruction. Autoimmune diseases can cause
ulti-organ involvement, but the primary end-organ target typ-
cally drives the clinical presentation and disease deﬁnition
2,12,21].
The mechanisms underlying immune mediated disorders are
iverse and complex, and are not fully understood to this day.
ndeed for some immune mediated diseases, an autoimmune
echanism has not been clearly demonstrated. Thus, a con-
ervative approach would be to collect data pertaining to all
ossible immune mediated diseases for which an autoimmune-
ependent mechanism has been postulated, even if not yet ﬁrmlyne 31 (2013) 1870– 1876 1871
established (for example, psoriasis, erythema nodosum, and many
others).
Vaccine clinical trials are conducted in a variety of settings
and by clinical teams with varying interests and specialties.
Adverse events are most frequently reported through the inves-
tigator. Therefore, investigators need to be encouraged in the
prospective, standardised collection of high quality safety data,
and be given tools to facilitate this process. To this end, a list
of pIMDs included in study documents would focus investiga-
tors’ attention on those events (regardless of seriousness), and
encourage prospective reporting of any new pIMD or exacerba-
tion of a pre-existing pIMD (serious or non-serious) in a study
subject. This list of pIMDs could be limited to speciﬁc disor-
ders that likely represent an autoimmune or immune mediated
inﬂammatory process. Disease-speciﬁc standard questionnaires
provided at study start would facilitate timely and thorough
documentation of these AESIs. An example of the type of data
to be collected on a disease speciﬁc questionnaire for Guillain-
Barré syndrome is given in Table 1. Finally, centralised, external
expert review of histopathology samples or other specialised diag-
nostic data is sometimes useful for diagnosis ascertainment in
selected cases with a suspected causal association with the study
vaccine.
Table 2 shows a proposed, non-exhaustive list of pIMDs that
could be included in a study protocol as AESI. Any list proposed
for inclusion in study protocols needs to balance sensitivity and
speciﬁcity. A list of corresponding terms for each disease linked to a
terminology dictionary would facilitate database encoding and tar-
geted periodic searches for safety monitoring. To increase detection
of these events, investigators should be asked to exercise his/her
medical and scientiﬁc judgement in identifying any other reported
diseases/disorders (other than those proposed by the sponsor in
study protocols) having a possible autoimmune origin as a pIMD,
based on the available clinical information. It is important to reit-
erate that the list of pIMDs given in Table 2 is not exhaustive given
the ongoing evolution of this ﬁeld. For example, diabetes melli-
tus type II is not included in Table 2, but recent data suggest that
type II diabetes may  be an autoimmune mediated disease [22,23].
Furthermore, many immune-mediated diseases have symptoms
that are non-speciﬁc (such as ‘arthralgia’) which also have a high
prevalence in the general population. Thus, symptoms, signs or con-
ditions without evidence of pathophysiology involving pathogenic
immune processes and for which further clinical investigation and
immunological tests must be done to explore the possibility of a
putative autoimmune origin should be recorded and reported as
adverse events, but not as pIMDs, until the ﬁnal or deﬁnitive diag-
nosis has been determined, and alternative diagnoses have been
eliminated or shown to be less likely.
3. Exacerbation of existing pIMDs
It has been a matter of debate whether vaccination has the
potential to exacerbate pre-existing autoimmune diseases. Con-
cerns that vaccination in subjects with pIMD might trigger a
ﬂare, affecting the course of disease or disease activity, have
been postulated often in case reports or in studies of small
numbers of subjects [24–27].  Investigations of selected vac-
cines and diseases have generally failed to identify causal links
[2,14,28–37], although not all vaccine-disease combinations have
been evaluated. In this respect, the collection of adverse events
related to an exacerbation of a pre-existing pIMD after vacci-
nation should also be considered. In these cases clinical status
evaluation and laboratory testing before vaccination may  be
required to distinguish between new onset and pre-existing dis-
ease.
1872 F. Tavares Da Silva et al. / Vaccine 31 (2013) 1870– 1876
Table 1
Example of data to be collected in the event of a pIMD, in this case, Guillain-Barré syndrome (GBS).
Reporter details Report date
• Reporter name/contact information/qualiﬁcations/location
Vaccinee demographic details • Case or study participant identiﬁers/date of birth (gestational age and weight at birth, APGAR score if applicable).
Clinical  and immunisation history
of the subject
• Medical history of any pre-immunisation condition including pre-vaccination neurological status
•  Drug/toxin and medication history
Immunisation history
• Details (clinical or laboratory) of antecedent infectious illness within 6 weeks prior to onset of neurologic signs
•  Immunisation details including date/description/lot/site/administration route
Description of the adverse event • Criteria fulﬁlling the case deﬁnition and other signs/symptoms indicative of GBS, including autonomic manifestations
•  Description of clinical manifestations and course including clinical ﬁndings, laboratory features, electrophysiologic features
suggestive of GBS:
-  Severity of weakness at clinical nadir
-  Disease duration between clinical onset and nadir
-  Additional neurologic signs
- Concurrent signs, symptoms, and diseases
- Results of all electroneuromyographic studies
-  Results of neurophysiologic studies, including electroencephalography and neuroimaging studies
-  Results of cerebrospinal ﬂuid examination
- Results of antiglycolipids antibodies
- Additional laboratory testing results identifying an aetiology other than GBS
•  Date/time of onset. First observation of diagnosis
•  Results of neurologic consultation including assessment of:
-  Manual Muscle Testing (Medical Research Council Scale)
-  Deep tendon reﬂexes
- Sensory examination
-  Cranial nerve
-  Presence or absence of ataxia
- Modiﬁed Rankin Functional Score
-  GBS disability score
• Regular measurement of clinical parameters at:
-  Initial presentation
- Clinical nadir
-  Points of signiﬁcant clinical change
-  Recovery
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. Onset and duration of data collection
It is not uncommon that the ﬁrst signs and symptoms of a pIMD
an occur months to years before a diagnosis is made. For many dis-
ases the time to disease onset after a triggering event is unknown.
hus, both the time to onset and the time to diagnosis are highly
ariable, depending on the disease concerned and the individual
ffected. Consequently, the pIMD data collection period in vaccine
linical trials has to be determined using a theoretical risk period
fter the last vaccination, where the likelihood of observing an
ncreased risk for developing potential immune mediated disorders
ould be highest if there was a causal link between the disease and
accination. This theoretical risk interval should ideally be deter-
ined based on the onset of the disease (either acute or insidious),
ossible or known pathologic mechanisms involved, and the type
f vaccine [39]. To date, few references have formally assessed and
etermined biologically plausible and evidence-based risk inter-
als in immunisation safety research. For Guillain-Barré syndrome,
he period of increased risk was shown to be concentrated within
 weeks after the 1976–1977 swine ﬂu vaccination [13,14]. There-
ore a 6 week time window is generally used for the assessment of
ases of Guillain-Barré syndrome potentially associated with vac-
ines [16,40].  For acute disseminated encephalomyelitis following
mmunisation, the risk interval also appears to decrease substan-
ially beyond 6 weeks after vaccination [39]. Also, the possibility of
 longer interval between vaccination and disease onset cannot be
xcluded, in particular for diseases with an insidious onset such as
ultiple Sclerosis or rheumatic diseases.
Whatever the underlying mechanisms, one may  assume that the
evelopment of autoimmunity (if a causal association between the
vent and vaccination existed) requires several weeks to develop;
hich is similar to the classical time frame of several weekson/clinical status/ongoing treatment
suggested for the onset of post-infectious autoimmune phenom-
ena. The risk becomes very low several months following the last
vaccine dose received. Assuming that in the hypothetical event
of a causal association, the development of autoimmunity after
vaccination requires a few weeks to develop, but is likely to be less
than a few months following vaccination: thus, in the absence of
deﬁnitive biological or epidemiological data, we  propose that one
year after the last vaccination would be a reasonable maximum
theoretical risk interval for new onset of autoimmune diseases.
There are limited data to suggest the shortest risk interval
between provision of an antigenic stimulus (e.g., natural infection),
the mounting of a subsequent immunologic response, and onset
of clinical immune-mediated disease [39,41].  An initial interval
(the time window following vaccination during which an event, if
it occurred, has no biological plausibility to have been triggered
by vaccination), may  also be considered when analysing pIMD
data reported after vaccination. Assuming that the risk window
begins immediately post-vaccination, we  advocate data collection
commencing immediately after vaccination is given. However, tak-
ing into account the biologic mechanisms by which autoimmune
responses are generated and how they might lead to clinically
observable illnesses, in addition to the known kinetics of primary
and secondary antibody responses after exposure to vaccine anti-
gens, an interval of less than 5–7 days post-vaccination would seem
to be biologically implausible for a possible vaccine-induced pIMD
[42,43].
5. Identiﬁcation of predictive markers for potential
immune mediated disorders in clinical trials
Biomarkers in clinical medicine are generally used to facilitate
or conﬁrm a diagnosis, to aid prognosis and to evaluate clinical
F.
 Tavares
 D
a
 Silva
 et
 al.
 /
 V
accine
 31 (2013) 1870– 1876
1873
Table 2
Suggested list of potential immune mediated disorders (pIMDs) of interest for possible evaluation in clinical vaccine studies.a
Neuroinﬂammatory disorders Musculoskeletal disorders Skin disorders
Cranial nerve inﬂammatory disorders, including paralyses/paresis
(e.g., Bell’s palsy)
Systemic lupus erythematosus
Systemic sclerosis (with limited or diffuse cutaneous involvement)
Psoriasis
Vitiligo
Optic neuritis Dermatomyositis Erythema nodosum
Multiple sclerosis Polymyositis Autoimmune bullous skin diseases (including pemphigus, pemphigoid &
dermatitis herpetiformis)
Transverse myelitis Anti-synthetase syndrome Cutaneous lupus erythematosus
Acute  disseminated encephalomyelitis including site- speciﬁc
variants: encephalitis, encephalomyelitis, myelitis,
myeloradiculoneuritis, cerebellitis
Rheumatoid arthritis Alopecia areata
Myasthenia gravis (including Lambert-Eaton myasthenic syndrome) Juvenile chronic arthritis (including Still’s disease) Lichen planus
Immune mediated peripheral neuropathies and plexopathies,
(including Guillain-Barré syndrome, Miller Fisher syndrome and
other variants, chronic inﬂammatory demyelinating
polyneuropathy, multifocal motor neuropathy and
polyneuropathies associated with monoclonal gammopathy)
Polymyalgia rheumatica
Spondyloarthritis, including ankylosing spondylitis, reactive arthritis
(Reiter’s Syndrome) and undifferentiated spondyloarthritis
Psoriatic arthropathy
Relapsing polychondritis
Mixed connective tissue disorder
Sweet’s syndrome
Morphoea
Narcolepsy
Liver disorders Gastrointestinal disorders Metabolic & endocrine disorders
Autoimmune hepatitis Crohn’s disease Autoimmune thyroiditis (including Hashimoto thyroiditis)
Primary  biliary cirrhosis Ulcerative colitis Grave’s or Basedow’s disease
Primary  sclerosing cholangitis Ulcerative proctitis Diabetes mellitus type I
Autoimmune cholangitis. Celiac disease Addison’s disease
Vasculitides Others
Large vessels vasculitis including: giant cell arteritis such as
Takayasu’s arteritis & temporal arteritis
Autoimmune haemolytic anaemia
Autoimmune thrombocytopenia
Medium sized and/or small vessels vasculitis including:
polyarteritis nodosa, Kawasaki’s disease, microscopic
polyangiitis, Wegener’s granulomatosis, Churg–Strauss
syndrome (allergic granulomatous angiitis), Buerger’s disease
(thromboangiitis obliterans), necrotising vasculitis &
anti-neutrophil cytoplasmic antibody (ANCA) positive vasculitis
(type unspeciﬁed), Henoch-Schonlein purpura, Behcet’s
syndrome, leukocytoclastic vasculitis
Antiphospholipid syndrome
Pernicious anaemia
Autoimmune glomerulonephritis (including IgA nephropathy,
glomerulonephritis rapidly progressive, membranous glomerulonephritis,
membranoproliferative glomerulonephritis, & mesangioproliferative
glomerulonephritis)
Uveitis
Autoimmune myocarditis/cardiomyopathy
Sarcoidosis
Stevens-Johnson syndrome
Sjögren’s syndrome
Idiopathic pulmonary ﬁbrosis
Goodpasture syndrome
Raynaud’s phenomenon
a Note that this table is not intended to be exhaustive, but is indicative of the type of conditions that could be included as adverse events of special interest (AESI) in clinical trials.
1  Vacci
p
i
m
d
t
s
b
d
c
t
i
d
p
i
a
f
a
c
c
f
n
m
5
m
d
c
i
a
a
v
c
i
a
t
t
t
s
h
s
a
a
b
d
s
t
m
a
o
t
e
n
c
t
s
t
l
a
i
a874 F. Tavares Da Silva et al. /
rogression and response to treatment. The ideal biomarker of
mmune mediated diseases would be one with a deﬁned nor-
al  range that becomes abnormal when a speciﬁc autoimmune
isease develops, that changes in proportion to disease severity,
hat becomes normal during remission, and that is detectable in
erum. Autoimmune disease biomarkers under investigation may
e grouped into three broad areas encompassing tissue degra-
ation products; enzymes implicated in tissue degradation; and
ytokines/other proteins that play a role in immune system activa-
ion and inﬂammation [44].
Biobanked samples obtained from study participants, specif-
cally serum or plasma, at study start would enable testing for
iagnostic, prognostic or predictive markers in subjects in whom a
IMD or disease ﬂare was diagnosed during the study period. The
nformation on the presence or absence of these markers before
dministration of the ﬁrst vaccine dose would allow, in some cases,
or a better causality assessment of pIMD cases that are reported
fter vaccination. However, the establishment of biobanks in the
linical trial setting may  entail multiple challenges, including high
ost, infrastructure and resources, difﬁculties obtaining consent
rom participants, potential liability issues, and the extensive plan-
ing required to ensure the quality and availability of samples that
ight also be amenable to future investigations.
.1. Autoantibodies
Pathogenic autoantibodies directed against membrane antigens
ay  be causative of disease. For some diseases such as Grave’s
isease, myasthenia gravis, pemphigus, and others, it has been
learly demonstrated that autoantibodies directly mediate the clin-
cal phenotype and/or organ damage. Nevertheless, the value of
utoimmune antibody testing in clinical trials for those pIMD where
utoimmune antibodies have a known diagnostic or predictive
alue is not clear. The presence of autoantibodies is not in itself
onsidered synonymous with autoimmune disease, as other clin-
cal conditions (such as cancer, acute tissue damage) may  also be
ssociated with their presence [21]. In addition, while the detec-
ion of speciﬁc autoantibodies in serum is an important diagnostic
ool for some autoimmune diseases [45,46],  autoantibodies are
ypically poor biomarkers for reasons related to speciﬁcity, sen-
itivity and technical issues linked to their measurement. Normal
uman serum contains a spectrum of autoantibodies which are poly
peciﬁc and present low afﬁnity for a variety of autoantigens. Auto-
ntibodies may  be detected in normal individuals (for example,
pproximately 30% of normal persons have an anti-nuclear anti-
ody titre ≥1:40 [47]), as well as in patients with autoimmune
isease and patients with other inﬂammatory diseases. Moreover,
peciﬁc autoantibodies may  be detectable in the serum years before
he onset of clinical disease.
Further complicating assessment of laboratory results, autoim-
une diseases commonly have diagnostically overlapping features,
 number of nonspeciﬁc constitutive manifestations and a variety
f possible autoantibody proﬁles. Autoantibody positivity may  be
ransient, that is, the autoantibodies may  disappear without any
vidence of clinical disease, and autoantibody levels generally do
ot ﬂuctuate in relation to disease severity.
Inter-laboratory variation in detection methods including assay
ut-off values, test validity and precision also hampers interpre-
ation of results [48,49]. Different tests vary considerably in their
peciﬁcity, sensitivity and clinical signiﬁcance. The speciﬁcity of
ests for target diseases differs between individuals with simi-
ar disorders, and the predictive value of the test is considerably
ffected by the prevalence of the target disease [50–54].
Based on these features it is apparent that autoantibody positiv-
ty does not necessarily lead to a diagnosis of autoimmune disease
nd it cannot always be easily correlated with disease onset. Indeed,ne 31 (2013) 1870– 1876
the diagnostic accuracy of speciﬁc autoantibodies is extremely
variable depending on different diseases and different autoanti-
gen/autoantibody systems [45]. Pre-exposure testing for autoan-
tibodies may, however, be useful for a few speciﬁc autoimmune
diseases for which the speciﬁcity of an autoantibody is well estab-
lished (e.g., islet-speciﬁc antibodies for diabetes mellitus type 1).
5.2. Non-autoantibody biomarkers
Currently, non-autoantibody biomarkers for autoimmune dis-
eases are being used as research tools but have not demonstrated
utility as clinical tools. This is because some non-autoantibody
biomarkers may  reach abnormal levels in individuals without
clinical symptoms or signs of disease; there is a lack of assay
standardisation between laboratories in terms of procedures and
antigens tested; and both levels of speciﬁc biomarkers and symp-
toms may  vary in subjects suffering from the same immune
mediated disease. Nevertheless, blood samples are frequently col-
lected in subjects prior to vaccination and analysis of both baseline
samples and samples obtained at the time of the pIMD may provide
valuable information in the future. For example, collected samples
could feasibly be analysed for new biomarkers well after study com-
pletion, using “omic”-based approaches, which may be useful for
safety assessments (e.g., genomic testing could aid identiﬁcation of
subsets of people at risk for certain adverse events) [55–57].
6. Signal detection and evaluation
Signal detection relies on a combination of individual and aggre-
gate medical case review. All adverse events reported as pIMDs to
investigators during the course of a clinical trial need to be medi-
cally assessed to conﬁrm the diagnosis as deﬁnitively as possible,
and to obtain relevant clinical data.
For the purposes of signal detection and analysis of data, pIMDs
can be coded and retrieved from databases using pre-deﬁned
groups of terms linked to a terminology dictionary, or by construc-
ting a customised query, which are intended to aid in identifying
cases that are highly likely to represent these cases of interest.
Individual case reports need to be evaluated by a medically qual-
iﬁed person to conﬁrm the diagnosis and thereby identify true cases
of interest among the whole batch of potential cases identiﬁed
by the search. When available, generally accepted case deﬁnitions
have an important role in guiding the identiﬁcation of true cases of
interest, greatly facilitate the meaningful assessment of the safety
data and allow for comparability of study results. Therefore, the use
of standardised case deﬁnitions is strongly encouraged for inte-
grated safety analyses [58]. Some standard case deﬁnitions are
publicly available and are accepted as a reference by the general
medical community. These include algorithms for the diagnosis of a
disease, for example multiple sclerosis [59,60],  and a growing num-
ber of standardised case deﬁnitions, such as those developed by the
Brighton Collaboration (http://www.brightoncollaboration.org) for
Guillain-Barré syndrome [38], encephalitis, myelitis and acute dis-
seminated encephalomyelitis [61]. Medical evaluation generally
differentiates individual cases into different levels of diagnostic cer-
tainty (i.e., levels of evidence for a reported event meeting the case
deﬁnition): cases where the diagnosis is considered as conﬁrmed,
cases reported without sufﬁcient information to conclude on diag-
nostic certainty, and cases for which the diagnosis is excluded.
Conﬁrmed and possible cases are generally considered for further
data analysis.
Disease activity is generally assessed by the presence of clinical
symptoms or standardised clinical disease activity scores. A num-
ber of disease activity scores have been established and generally
accepted for several autoimmune diseases. They include scores for
rheumatoid arthritis [62,63],  ankylosing spondylitis [64], systemic
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upus erythematosus [65] and vasculitis [66]. Activity scores in con-
unction with case deﬁnitions provide a means of assessing disease
everity of new onset disease, as well as evaluating exacerbations
n individuals with pre-existing immune mediated illnesses.
. Limitations of preapproval studies to detect rare events
Safety is assessed in all phases of vaccine clinical development
nd should continue throughout its life cycle. Randomised con-
rolled trials are the principal means of establishing the safety and
fﬁcacy of vaccines. However pre-approval trials are usually limited
n size and duration and exclude high-risk populations, so they may
ave limited statistical power to detect rare but potentially seri-
us adverse events. Effective safety data collection in clinical trials
equires speciﬁc attention to facilitate its meaningful comparison
nd interpretation. Furthermore, a thorough medical assessment
f relatively rare adverse events, such as those related to autoim-
unity, is essential; as the occurrence of a single event may  raise
oncerns, for which the quality of the data becomes critical.
. Conclusion
This review considers means by which safety data gathering
an be optimised in the clinical trial setting. Standardised collec-
ion of safety data aims to minimise under or over reporting and to
aximise the quality of medical information that is collected to
llow diagnostic certainty and causality assessment in individual
ases. Emphasis on the importance of collection of high quality
afety data to investigators can be achieved through the use of
IMD lists and targeted disease questionnaires. Data collection
ver a deﬁned risk period, expert review of diagnostic tests and
entralised, systematic case review using accepted clinical case def-
nitions will allow more reliable assessments of potential causal
elationships between speciﬁc pIMDs and vaccination. In the future,
etection of biomarkers and/or autoantibodies may  offer improved
iagnostic accuracy, or prognostic and predictive utility.
Nonetheless, safety information gained in pre-licensure clin-
cal trials represents just one means by which vaccine safety is
onitored. The number of subjects in such trials may  still not be
arge enough for the assessment of the potential for the vaccine to
e associated with very rare adverse reactions. Post-approval tar-
eted safety studies speciﬁcally planned or conducted to examine
n actual or hypothetical safety concern between speciﬁc pIMDs
nd vaccination are sometimes required [67]. Studies conducted
n patients with autoimmune diseases are of particular interest to
xclude the risk of disease enhancement after vaccination [68]. Vac-
ines are administered to much larger populations after licensure
han is possible during clinical trials. Therefore, ongoing post-
icensure safety monitoring is essential in the continuing evaluation
f vaccine safety [35].
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